Skip to main content

Table 3 Multivariate analyses

From: Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trial

Factor HR (95% CI) (p value to exclude from model)
Model 1* (all pts) Model 2* (all pts) Model 3* (all pts) Model 4* (all pts)
Fixed variables     
Age (years) 1.01 (0.99, 1.02) 1.01 (1.00, 1.02) 1.01 (1.00, 1.02) 1.00 (0.98, 1.02)
 Tumour grade     
  III 1 1 1 1
  IV 1.84 (1.10, 3.08) 2.25 (1.33, 3.83) 2.43 (1.48, 3.98) 1.53 (0.81, 2.92)
WHO Performance status     
  0 1 1 1 1
  1 0.86 (0.58, 1.27) 0.93 (0.63, 1.39) 0.93 (0.63, 1.38) 0.79 (0.51, 1.21)
  2 1.42 (0.93, 2.17) 1.63 (1.06, 2.53) 1.62 (1.05, 2.50) 1.39 (0.87, 2.22)
  3 1.23 (0.69, 2.20) 1.54 (0.85, 2.81) 1.46 (0.93, 2.97) 1.64 (0.88, 3.06)
Gender     
  Male 1 1 1 1
  Female 0.80 (0.59, 1.07) 0.82 (0.61, 1.10) 0.80 (0.57, 1.03) 0.91 (0.66, 1.25)
Additional independent factors     
IDH1     
Normal 1 1   1
 Mutated 0.45 (0.29, 0.67) (p < 0.001) 0.58 (0.37, 0.91) (p = 0.015)   0.32 (0.18, 0.56) (P < 0.001)
PTEN     
Normal    1  
Hemizygous deletion    1.83 (1.29, 2.61)  
Homozygous deletion    1.47 (0.68, 3.16) P = 0.003  
MGMT methylation     
<10%   1 1 1
≥10%   0.59 (0.42, 0.82) P = 0.002 0.49 (0.36, 0.67) (p < 0.001) 0.44 (0.30, 0.63) (p = 0.002)
  1. *Model 1: mutation data only, final backwards stepwise selection model.
  2. Model 2: addition of MGMT methylation status to Model 1.
  3. Model 3: final backwards stepwise model including mutation data and MGMT methylation status.
  4. Model 4: final backwards stepwise model including mutation data and MGMT methylation status, MGMT hemizygous deletion patients only.